March 19, 2018 / 8:57 PM / 4 months ago

BRIEF-Arena Pharmaceuticals Reports Positive Phase 2 Results For Oasis Trial For Etrasimod

March 19 (Reuters) - Arena Pharmaceuticals Inc:

* ARENA PHARMACEUTICALS REPORTS POSITIVE PHASE 2 RESULTS FOR THE OASIS TRIAL FOR ETRASIMOD IN PATIENTS WITH ULCERATIVE COLITIS

* HIGH DOSE ETRASIMOD GROUP ACHIEVED STATISTICALLY SIGNIFICANT IMPROVEMENT IN CLINICAL REMISSION IN STUDY

* TRIAL MET PRIMARY, SECONDARY ENDPOINTS WITH STATISTICAL SIGNIFICANCE FOR PATIENTS GETTING HIGH DOSE ETRASIMOD FOR 12 WKS

* ETRASIMOD WAS WELL TOLERATED, HAD FEWER PATIENTS WITH SERIOUS ADVERSE EVENTS VERSUS PLACEBO IN STUDY

* IMPACT ON HEART RATE, ATRIOVENTRICULAR (AV) CONDUCTION LOW IN STUDY WITH NO DISCONTINUATIONS RELATED TO BRADYCARDIA OR AV BLOCK

* NO INCREASES IN LIVER FUNCTION TESTS VERSUS PLACEBO, NO REPORTS OF MACULAR EDEMA OR PULMONARY FUNCTION TEST ABNORMALITIES IN STUDY

* INTENDS TO INITIATE PHASE 3 PROGRAM IN ULCERATIVE COLITIS Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below